Floatz logo

Prevnar 20

Pneumococcal Infection

Poitiers University HospitalvaccinePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pneumococcal Infection cohort.

Asset / SponsorPhaseRating
Conjugated Pneumococcal Vaccine
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 4BBB
Prevenar 13
Poitiers University Hospital
Phase 4BBB
Ppsv23
Poitiers University Hospital
Phase 4BB
Prevnar 13
Merck Sharp & Dohme LLC
Phase 3BB
v114
Merck Sharp & Dohme LLC
Phase 3BB

View all 9 →

Same molecule, other indications

Prevnar 20 is also rated in:

non-Hodgkin lymphomaActive
B
Indicative · Phase 4
59 / 100
View asset →
lymphomaActive
B
Indicative · Phase 4
56 / 100
View asset →
sickle cell diseaseActive
CCC
Indicative · Phase 3
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →